nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—Psychotic depression—Riluzole—amyotrophic lateral sclerosis	0.0498	0.07	CcSEcCtD
Epoprostenol—Major depression—Riluzole—amyotrophic lateral sclerosis	0.0387	0.0545	CcSEcCtD
Epoprostenol—Peripheral vascular disorder—Riluzole—amyotrophic lateral sclerosis	0.0213	0.0299	CcSEcCtD
Epoprostenol—Pneumothorax—Riluzole—amyotrophic lateral sclerosis	0.021	0.0295	CcSEcCtD
Epoprostenol—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.0175	0.0247	CcSEcCtD
Epoprostenol—Enlargement abdomen—Riluzole—amyotrophic lateral sclerosis	0.0173	0.0244	CcSEcCtD
Epoprostenol—Hypoxia—Riluzole—amyotrophic lateral sclerosis	0.0164	0.0231	CcSEcCtD
Epoprostenol—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.015	0.0211	CcSEcCtD
Epoprostenol—Cyanosis—Riluzole—amyotrophic lateral sclerosis	0.0147	0.0207	CcSEcCtD
Epoprostenol—PTGIS—Nicotinamide salvaging—PTGS2—amyotrophic lateral sclerosis	0.0145	0.0723	CbGpPWpGaD
Epoprostenol—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.0136	0.0192	CcSEcCtD
Epoprostenol—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.0134	0.0188	CcSEcCtD
Epoprostenol—PTGIR—hindbrain—amyotrophic lateral sclerosis	0.0132	0.149	CbGeAlD
Epoprostenol—PTGIR—Endothelin Pathways—ECE1—amyotrophic lateral sclerosis	0.0131	0.0652	CbGpPWpGaD
Epoprostenol—PTGIS—Defective AMN causes hereditary megaloblastic anemia 1—TPK1—amyotrophic lateral sclerosis	0.0127	0.0636	CbGpPWpGaD
Epoprostenol—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.0126	0.0177	CcSEcCtD
Epoprostenol—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.0115	0.0161	CcSEcCtD
Epoprostenol—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.0106	0.0148	CcSEcCtD
Epoprostenol—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.0104	0.0147	CcSEcCtD
Epoprostenol—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.0104	0.0146	CcSEcCtD
Epoprostenol—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.00959	0.0135	CcSEcCtD
Epoprostenol—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00929	0.0131	CcSEcCtD
Epoprostenol—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00906	0.0127	CcSEcCtD
Epoprostenol—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00843	0.0119	CcSEcCtD
Epoprostenol—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00796	0.0112	CcSEcCtD
Epoprostenol—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00779	0.011	CcSEcCtD
Epoprostenol—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00776	0.0109	CcSEcCtD
Epoprostenol—PTGIS—Nicotinate metabolism—PTGS2—amyotrophic lateral sclerosis	0.00771	0.0385	CbGpPWpGaD
Epoprostenol—PTGIR—brainstem—amyotrophic lateral sclerosis	0.00757	0.0856	CbGeAlD
Epoprostenol—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00692	0.00973	CcSEcCtD
Epoprostenol—PTGIS—nervous system—amyotrophic lateral sclerosis	0.00691	0.0781	CbGeAlD
Epoprostenol—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.0067	0.00942	CcSEcCtD
Epoprostenol—PTGIS—central nervous system—amyotrophic lateral sclerosis	0.00665	0.0752	CbGeAlD
Epoprostenol—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00659	0.00927	CcSEcCtD
Epoprostenol—PTGER1—nervous system—amyotrophic lateral sclerosis	0.00642	0.0726	CbGeAlD
Epoprostenol—PTGIS—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—amyotrophic lateral sclerosis	0.00635	0.0317	CbGpPWpGaD
Epoprostenol—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00628	0.00882	CcSEcCtD
Epoprostenol—P2RY12—nervous system—amyotrophic lateral sclerosis	0.00622	0.0703	CbGeAlD
Epoprostenol—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00622	0.00874	CcSEcCtD
Epoprostenol—PTGER1—central nervous system—amyotrophic lateral sclerosis	0.00618	0.0699	CbGeAlD
Epoprostenol—PTGIS—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.00613	0.0306	CbGpPWpGaD
Epoprostenol—P2RY12—central nervous system—amyotrophic lateral sclerosis	0.00599	0.0677	CbGeAlD
Epoprostenol—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00592	0.00833	CcSEcCtD
Epoprostenol—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00587	0.00825	CcSEcCtD
Epoprostenol—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00584	0.00821	CcSEcCtD
Epoprostenol—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00584	0.00821	CcSEcCtD
Epoprostenol—Depression—Riluzole—amyotrophic lateral sclerosis	0.00582	0.00818	CcSEcCtD
Epoprostenol—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00575	0.00809	CcSEcCtD
Epoprostenol—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00572	0.00804	CcSEcCtD
Epoprostenol—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00567	0.00798	CcSEcCtD
Epoprostenol—Sweating—Riluzole—amyotrophic lateral sclerosis	0.0056	0.00787	CcSEcCtD
Epoprostenol—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00557	0.00782	CcSEcCtD
Epoprostenol—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00551	0.00774	CcSEcCtD
Epoprostenol—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00548	0.0077	CcSEcCtD
Epoprostenol—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00533	0.0075	CcSEcCtD
Epoprostenol—PTGIS—brain—amyotrophic lateral sclerosis	0.00528	0.0597	CbGeAlD
Epoprostenol—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00527	0.0074	CcSEcCtD
Epoprostenol—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00525	0.00739	CcSEcCtD
Epoprostenol—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00524	0.00737	CcSEcCtD
Epoprostenol—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00521	0.00733	CcSEcCtD
Epoprostenol—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.0052	0.00731	CcSEcCtD
Epoprostenol—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00516	0.00726	CcSEcCtD
Epoprostenol—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00515	0.00724	CcSEcCtD
Epoprostenol—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00486	0.00684	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—RARA—amyotrophic lateral sclerosis	0.00485	0.0242	CbGpPWpGaD
Epoprostenol—P2RY12—brain—amyotrophic lateral sclerosis	0.00476	0.0538	CbGeAlD
Epoprostenol—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00475	0.00668	CcSEcCtD
Epoprostenol—P2RY12—Signal amplification—PLA2G4A—amyotrophic lateral sclerosis	0.00475	0.0237	CbGpPWpGaD
Epoprostenol—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00472	0.00664	CcSEcCtD
Epoprostenol—PTGIR—spinal cord—amyotrophic lateral sclerosis	0.00471	0.0532	CbGeAlD
Epoprostenol—Chills—Riluzole—amyotrophic lateral sclerosis	0.0047	0.00661	CcSEcCtD
Epoprostenol—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00459	0.00645	CcSEcCtD
Epoprostenol—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.0045	0.00632	CcSEcCtD
Epoprostenol—PTGER1—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.00448	0.0224	CbGpPWpGaD
Epoprostenol—PTGIR—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.00448	0.0224	CbGpPWpGaD
Epoprostenol—Tension—Riluzole—amyotrophic lateral sclerosis	0.00448	0.00629	CcSEcCtD
Epoprostenol—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00443	0.00623	CcSEcCtD
Epoprostenol—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00441	0.0062	CcSEcCtD
Epoprostenol—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00439	0.00617	CcSEcCtD
Epoprostenol—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00427	0.00601	CcSEcCtD
Epoprostenol—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00422	0.00593	CcSEcCtD
Epoprostenol—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00419	0.00589	CcSEcCtD
Epoprostenol—PTGIS—Eicosanoid Synthesis—PTGS2—amyotrophic lateral sclerosis	0.00413	0.0206	CbGpPWpGaD
Epoprostenol—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00409	0.00575	CcSEcCtD
Epoprostenol—PTGIS—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.00407	0.0203	CbGpPWpGaD
Epoprostenol—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00403	0.00567	CcSEcCtD
Epoprostenol—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00401	0.00564	CcSEcCtD
Epoprostenol—Cough—Riluzole—amyotrophic lateral sclerosis	0.00398	0.0056	CcSEcCtD
Epoprostenol—PTGIR—nervous system—amyotrophic lateral sclerosis	0.00397	0.0449	CbGeAlD
Epoprostenol—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00388	0.00546	CcSEcCtD
Epoprostenol—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00388	0.00546	CcSEcCtD
Epoprostenol—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00388	0.00546	CcSEcCtD
Epoprostenol—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00387	0.00544	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00386	0.00542	CcSEcCtD
Epoprostenol—PTGIR—central nervous system—amyotrophic lateral sclerosis	0.00382	0.0432	CbGeAlD
Epoprostenol—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.0038	0.00534	CcSEcCtD
Epoprostenol—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00375	0.00528	CcSEcCtD
Epoprostenol—PTGIR—cerebellum—amyotrophic lateral sclerosis	0.00373	0.0422	CbGeAlD
Epoprostenol—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00372	0.00523	CcSEcCtD
Epoprostenol—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00372	0.00523	CcSEcCtD
Epoprostenol—Infection—Riluzole—amyotrophic lateral sclerosis	0.0037	0.0052	CcSEcCtD
Epoprostenol—Shock—Riluzole—amyotrophic lateral sclerosis	0.00366	0.00515	CcSEcCtD
Epoprostenol—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00365	0.00513	CcSEcCtD
Epoprostenol—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00365	0.00512	CcSEcCtD
Epoprostenol—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00363	0.00511	CcSEcCtD
Epoprostenol—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00362	0.00508	CcSEcCtD
Epoprostenol—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.0036	0.00506	CcSEcCtD
Epoprostenol—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00355	0.00499	CcSEcCtD
Epoprostenol—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00348	0.00489	CcSEcCtD
Epoprostenol—PTGIS—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.00345	0.0172	CbGpPWpGaD
Epoprostenol—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—amyotrophic lateral sclerosis	0.00345	0.0172	CbGpPWpGaD
Epoprostenol—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00339	0.00477	CcSEcCtD
Epoprostenol—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00337	0.00473	CcSEcCtD
Epoprostenol—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00334	0.0047	CcSEcCtD
Epoprostenol—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00332	0.00467	CcSEcCtD
Epoprostenol—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00331	0.00465	CcSEcCtD
Epoprostenol—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00328	0.00461	CcSEcCtD
Epoprostenol—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00324	0.00455	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00321	0.00452	CcSEcCtD
Epoprostenol—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00321	0.00451	CcSEcCtD
Epoprostenol—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00318	0.00448	CcSEcCtD
Epoprostenol—Pain—Riluzole—amyotrophic lateral sclerosis	0.00318	0.00448	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00304	0.00428	CcSEcCtD
Epoprostenol—PTGIR—brain—amyotrophic lateral sclerosis	0.00303	0.0343	CbGeAlD
Epoprostenol—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00296	0.00416	CcSEcCtD
Epoprostenol—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00294	0.00414	CcSEcCtD
Epoprostenol—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00294	0.00414	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.00284	0.0142	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00274	0.00386	CcSEcCtD
Epoprostenol—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00267	0.00376	CcSEcCtD
Epoprostenol—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00263	0.0037	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.00259	0.013	CbGpPWpGaD
Epoprostenol—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00255	0.00358	CcSEcCtD
Epoprostenol—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.00253	0.0126	CbGpPWpGaD
Epoprostenol—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.00253	0.0126	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—TUBA4A—amyotrophic lateral sclerosis	0.00253	0.0126	CbGpPWpGaD
Epoprostenol—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00246	0.00346	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.00241	0.012	CbGpPWpGaD
Epoprostenol—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00237	0.00333	CcSEcCtD
Epoprostenol—Rash—Riluzole—amyotrophic lateral sclerosis	0.00235	0.0033	CcSEcCtD
Epoprostenol—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00235	0.0033	CcSEcCtD
Epoprostenol—Headache—Riluzole—amyotrophic lateral sclerosis	0.00233	0.00328	CcSEcCtD
Epoprostenol—PTGIS—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.0023	0.0115	CbGpPWpGaD
Epoprostenol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00229	0.0115	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—PFN1—amyotrophic lateral sclerosis	0.00227	0.0114	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.00227	0.0113	CbGpPWpGaD
Epoprostenol—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00221	0.00311	CcSEcCtD
Epoprostenol—PTGIR—Platelet homeostasis—PLA2G4A—amyotrophic lateral sclerosis	0.00209	0.0104	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.0019	0.00949	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.00188	0.00938	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.00173	0.00863	CbGpPWpGaD
Epoprostenol—PTGIS—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.00165	0.00823	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.00155	0.00776	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.00151	0.00755	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TPK1—amyotrophic lateral sclerosis	0.00151	0.00753	CbGpPWpGaD
Epoprostenol—PTGIS—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—amyotrophic lateral sclerosis	0.00147	0.00736	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.00139	0.00695	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.00139	0.00695	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.0013	0.0065	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—IGF1—amyotrophic lateral sclerosis	0.00129	0.00644	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00126	0.00631	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00126	0.00631	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.00121	0.00604	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—VTA1—amyotrophic lateral sclerosis	0.00121	0.00602	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.0012	0.00598	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.00118	0.00588	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.00117	0.00585	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00116	0.00577	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.00115	0.00575	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.00111	0.00556	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.0011	0.00549	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.00108	0.00539	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00107	0.00537	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.00106	0.00529	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.00106	0.00529	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00101	0.00504	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	0.000986	0.00492	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CHMP2B—amyotrophic lateral sclerosis	0.000914	0.00456	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—DAO—amyotrophic lateral sclerosis	0.000913	0.00456	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.00083	0.00414	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PLB1—amyotrophic lateral sclerosis	0.000827	0.00413	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—VCP—amyotrophic lateral sclerosis	0.000737	0.00368	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000692	0.00346	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	0.00067	0.00335	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.00066	0.00329	CbGpPWpGaD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000658	0.00329	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.00065	0.00325	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GSR—amyotrophic lateral sclerosis	0.000639	0.00319	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000607	0.00303	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000607	0.00303	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000599	0.00299	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000599	0.00299	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000595	0.00297	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000591	0.00295	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000582	0.00291	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.000567	0.00283	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000544	0.00271	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000544	0.00271	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CST3—amyotrophic lateral sclerosis	0.000529	0.00264	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000525	0.00262	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.000522	0.0026	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000508	0.00254	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000502	0.00251	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000479	0.00239	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000468	0.00234	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000462	0.00231	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000462	0.00231	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.00046	0.0023	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000458	0.00229	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	0.000438	0.00219	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000433	0.00216	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000424	0.00212	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000424	0.00212	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000419	0.00209	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.00041	0.00205	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000398	0.00199	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000398	0.00199	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000397	0.00198	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.00039	0.00195	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CASP9—amyotrophic lateral sclerosis	0.000384	0.00192	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000378	0.00189	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000378	0.00189	CbGpPWpGaD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000371	0.00185	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000366	0.00183	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000366	0.00183	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000366	0.00183	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000353	0.00176	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000349	0.00174	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.000346	0.00173	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—ERBB4—amyotrophic lateral sclerosis	0.000329	0.00164	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	0.000328	0.00164	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000325	0.00162	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000325	0.00162	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000321	0.0016	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000321	0.0016	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.000318	0.00159	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000292	0.00146	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000284	0.00142	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000282	0.00141	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000268	0.00134	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000268	0.00134	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000266	0.00133	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000263	0.00131	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000261	0.0013	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000261	0.0013	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000259	0.00129	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000258	0.00129	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—APOE—amyotrophic lateral sclerosis	0.000255	0.00127	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000251	0.00125	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.00024	0.0012	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000237	0.00118	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000237	0.00118	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—VEGFA—amyotrophic lateral sclerosis	0.000226	0.00113	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000225	0.00112	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000221	0.0011	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000221	0.0011	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000214	0.00107	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—APOE—amyotrophic lateral sclerosis	0.000213	0.00106	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—VEGFA—amyotrophic lateral sclerosis	0.000208	0.00104	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000207	0.00103	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000207	0.00103	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000204	0.00102	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000204	0.00102	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000197	0.000984	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000197	0.000984	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.00019	0.000951	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000187	0.000933	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000183	0.000915	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTGS2—amyotrophic lateral sclerosis	0.000174	0.000871	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000174	0.000867	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000172	0.000861	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—amyotrophic lateral sclerosis	0.000171	0.000852	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000169	0.000842	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000169	0.000842	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000163	0.000815	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000159	0.000792	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000159	0.000792	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—amyotrophic lateral sclerosis	0.000157	0.000784	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000152	0.000761	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	0.000148	0.000737	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000146	0.00073	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.000142	0.000708	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.00014	0.0007	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.00014	0.0007	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.00013	0.000652	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.00013	0.000652	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	0.000117	0.000585	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000112	0.000559	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	0.000108	0.000538	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	0.000108	0.000538	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	0.000103	0.000516	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	9.4e-05	0.00047	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.02e-05	0.00045	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.52e-05	0.000426	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	8.48e-05	0.000423	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.3e-05	0.000414	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.3e-05	0.000414	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.84e-05	0.000392	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.84e-05	0.000392	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	7.74e-05	0.000386	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.65e-05	0.000382	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.04e-05	0.000352	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.04e-05	0.000352	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.78e-05	0.000289	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.32e-05	0.000266	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.32e-05	0.000266	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	5.3e-05	0.000265	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.56e-05	0.000228	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.19e-05	0.000209	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	3.44e-05	0.000172	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.36e-05	0.000118	CbGpPWpGaD
